Press-release for stocks for eli lilly and company

Prices are updated after-hours

Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

entities : Eli lilly and company crawled time : 01:00

save search

Global IgG Mediated Autoimmune Diseases Biologic Drugs Research Report 2023-2029: Shift Towards Personalized Medicine and Targeted Therapies & Adoption of Biosimilars and Biobetters
Published: 2024-03-13 (Crawled : 01:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K

|

Health Technology

| -4.76% | O: -0.23% H: 0.0% C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M

|

Health Technology

| -6.71% | O: -0.07% H: 0.09% C: -0.7%
JNJ | News | $147.91 1.49% -0.03% 9.6M

|

Health Technology

| -10.2% | O: 0.66% H: 0.0% C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| -0.55% | O: 0.27% H: 0.5% C: 0.11%
ABBV | $166.41 1.06% 0.0% 5.5M

|

Health Technology

| -8.97% | O: 0.59% H: 0.01% C: -1.45%
SNY | News | $46.32 2.05% 2.01% 3.3M

|

Health Technology

| -5.85% | O: -0.04% H: 0.0% C: 0.0%
report research global

Global Human Growth Hormone Market Report 2024 - Rapid Development of New Novel Recombinant Human Growth Hormones is Forecast to Drive the Market Forward - A $8.73 Billion Forecasted Market by 2028
Published: 2024-03-12 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| 2.23% | O: 0.9% H: 2.03% C: 1.89%
report rapid global growth market hormone

Telemedicine Market Projected to Soar to US$ 317.59 Billion by 2030, Driven by High-tech Healthcare Services and Innovation
Published: 2024-03-01 (Crawled : 01:00) - prnewswire.com
TDOC S | $12.98 -1.52% 0.08% 5.3M

|

Health Services

| -12.86% | O: -0.13% H: 1.39% C: -0.4%
GE | News | $148.06 -3.19% 0.0% 9.5M

|

Electronic Technology

| -0.78% | O: 0.07% H: 1.48% C: 1.05%
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| -0.39% | O: 2.04% H: 1.96% C: 1.7%
services innovation market

Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Analysis Report 2024: A $133.5 Billion in 2030 Featuring Eli Lilly and Co, Pfizer, Sanofi, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk
Published: 2024-02-27 (Crawled : 01:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800

|

Health Technology

| 4.09% | O: -1.72% H: 2.54% C: 2.54%
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| -2.74% | O: -2.2% H: 2.39% C: 1.34%
SNY | News | $46.32 2.05% 2.01% 3.3M

|

Health Technology

| -6.76% | O: -0.94% H: 0.0% C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M

|

Health Technology

| 3.54% | O: 0.01% H: 0.79% C: 0.6%
report agonist global market

Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510

|

Health Technology

| -5.87% | O: 0.14% H: 0.0% C: -0.0%
SNYNF | News | $92.7 -2.18% 600K

|

Health Technology

| -3.13% | O: 0.26% H: 1.36% C: 1.36%
AZNCF | News | $138.24 -4.19% 800

|

Health Technology

| 6.54% | O: -0.85% H: 1.12% C: 0.43%
NVSEF | $93.6375 6.88% 82K

|

Health Technology

| -8.14% | O: 0.92% H: 0.0% C: 0.0%
UCBJY | $63.676 -4.38% 7.2K

|

| 25.87% | O: 1.46% H: 0.44% C: 0.44%
ALPMY | $9.47 -1.11% 520K

|

| -16.01% | O: -0.27% H: 0.0% C: -1.17%
TAK | News | $13.24 0.61% 0.0% 1.3M

|

Health Technology

| -10.79% | O: -0.2% H: 0.14% C: -0.48%
NVS | $94.36 1.93% 0.0% 2.3M

|

Health Technology

| -9.24% | O: -0.06% H: 0.46% C: 0.29%
GSK | News | $39.75 1.22% 0.0% 1.6M

|

Health Technology

| -5.58% | O: -0.69% H: 1.42% C: 1.22%
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| 0.65% | O: 2.37% H: 1.51% C: 0.79%
BMY | $48.93 1.3% 0.0% 10M

|

Health Technology

| -5.13% | O: -0.65% H: 1.63% C: 1.48%
ABBV | $166.41 1.06% 0.0% 5.5M

|

Health Technology

| -6.33% | O: -0.88% H: 1.46% C: 1.13%
SNY | News | $46.32 2.05% 2.01% 3.3M

|

Health Technology

| -3.44% | O: 1.67% H: 0.0% C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M

|

Health Technology

| 4.88% | O: -2.81% H: 2.08% C: 1.38%
AMGN | $269.03 2.39% 2.33% 3.4M

|

Health Technology

| -6.54% | O: -0.35% H: 1.15% C: 0.96%
lung reach cancer cell diagnostics therapy market

Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting
Published: 2023-12-12 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| 25.42% | O: -2.88% H: 0.0% C: 0.0%
cell meeting leukemia study

Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Published: 2023-12-06 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

|

Health Technology

| -1.66% | O: -2.77% H: 0.49% C: 0.49%
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| 28.8% | O: 0.99% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

|

Health Technology

| -2.23% | O: -0.6% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M

|

Health Technology

| -3.65% | O: -0.2% H: 1.7% C: 1.3%
rient-16 treatment results study

Medical Segment Dominates, Expected to Reach $70.4 Billion by 2030 in the Global Recombinant DNA Technology Market
Published: 2023-11-01 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510

|

Health Technology

| 12.22% | O: -1.62% H: 0.0% C: 0.0%
SNYNF | News | $92.7 -2.18% 600K

|

Health Technology

| 3.73% | O: 0.94% H: 2.55% C: 2.55%
NVSEF | $93.6375 6.88% 82K

|

Health Technology

| 2.99% | O: 2.52% H: 0.04% C: 0.04%
NVO | News | $122.71 -0.03% 0.17% 5M

|

Health Technology

| 28.95% | O: 0.87% H: 0.73% C: 0.28%
NVS | $94.36 1.93% 0.0% 2.3M

|

Health Technology

| -0.53% | O: 0.16% H: 0.7% C: 0.57%
GSK | News | $39.75 1.22% 0.0% 1.6M

|

Health Technology

| 10.92% | O: -4.06% H: 1.9% C: 0.96%
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| 32.11% | O: -2.76% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

|

Health Technology

| -0.11% | O: 0.18% H: 0.0% C: 0.0%
expected reach global dna medical technology market

Global Cancer Therapies Strategic Business Report 2023: Industry Focuses on New Approaches to Treat Cancer
Published: 2023-06-27 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510

|

Health Technology

| 11.2% | O: -1.1% H: 0.0% C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M

|

Health Technology

| -16.61% | O: -0.95% H: 0.19% C: -0.32%
PFE A | $26.0 2.4% -0.15% 38M

|

Health Technology

| -31.09% | O: 0.19% H: 0.11% C: -1.46%
NVS | $94.36 1.93% 0.0% 2.3M

|

Health Technology

| -6.46% | O: -0.01% H: 0.16% C: -0.32%
JNJ | News | $147.91 1.49% -0.03% 9.6M

|

Health Technology

| -11.42% | O: 0.03% H: 0.12% C: -0.24%
GSK | News | $39.75 1.22% 0.0% 1.6M

|

Health Technology

| 9.18% | O: -0.91% H: 0.56% C: -0.5%
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| 65.82% | O: 2.15% H: 1.18% C: 0.43%
BMY | $48.93 1.3% 0.0% 10M

|

Health Technology

| -25.45% | O: -0.06% H: 0.46% C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M

|

Health Technology

| -4.83% | O: -0.21% H: 0.42% C: 0.13%
report business cancer treat global

Advanced Renal Cell Carcinoma Drug Analysis Report 2023: Comprehensive Insights About 50+ Companies and 60+ Pipeline Drugs
Published: 2023-06-02 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| 72.0% | O: 0.79% H: 1.08% C: 0.54%
drug companies report renal pipeline cell

Transcenta Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density
Published: 2023-05-17 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| 71.94% | O: 0.49% H: 0.03% C: -0.3%
tst002 chinese bone

Innovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint
Published: 2023-05-11 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| 72.23% | O: 0.18% H: 0.03% C: -0.26%
SNY | News | $46.32 2.05% 2.01% 3.3M

|

Health Technology

| -15.88% | O: -0.28% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M

|

Health Technology

| -17.37% | O: 0.3% H: 0.12% C: 0.09%
ibi362 obesity chinese study

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
Published: 2023-04-18 (Crawled : 01:00) - globenewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M

|

Health Technology

| -21.16% | O: 0.9% H: 0.0% C: -0.71%
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| 101.63% | O: 0.17% H: 0.34% C: -0.83%
HCM | $16.49 0.8% 0.79% 61K

|

Health Technology

| -2.08% | O: 1.49% H: 2.64% C: 1.52%
china

Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023
Published: 2023-04-17 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

|

Health Technology

| -17.23% | O: -0.73% H: 0.0% C: -1.07%
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| 100.35% | O: 0.07% H: 0.24% C: -0.71%
SNY | News | $46.32 2.05% 2.01% 3.3M

|

Health Technology

| -19.48% | O: -0.65% H: 0.0% C: 0.0%
rient-15 cell treatment meeting plus results study

Pre Filled Syringes Global Market Report 2023: Connected Syringes to Reshape Industry Moving Forward
Published: 2023-04-05 (Crawled : 01:00) - prnewswire.com
TRUMF | $16.928 -17.59% 1.9K

|

Health Technology

| -38.11% | O: -1.89% H: 0.0% C: -0.97%
TRUMY | $16.507 0.79% 34K

|

| -38.89% | O: -0.87% H: 1.47% C: 0.76%
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| 111.71% | O: 0.98% H: 1.89% C: 1.16%
BMY | $48.93 1.3% 0.0% 10M

|

Health Technology

| -29.91% | O: 0.8% H: 1.07% C: 0.52%
ABBV | $166.41 1.06% 0.0% 5.5M

|

Health Technology

| 3.37% | O: 0.14% H: 1.04% C: 0.5%
report global market

Innovent Announces 2022 Annual Results and Business Updates
Published: 2023-03-29 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| 122.35% | O: 0.4% H: 0.23% C: -0.92%
SNY | News | $46.32 2.05% 2.01% 3.3M

|

Health Technology

| -15.92% | O: 1.07% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M

|

Health Technology

| -24.88% | O: 0.6% H: 0.69% C: 0.58%
business results

Global Peptide Antibiotics Market Report 2022: Sector to Reach $5.74 Billion in 2026 at a CAGR of 8%
Published: 2023-03-28 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510

|

Health Technology

| 18.75% | O: 3.17% H: 0.0% C: 0.0%
PFE A | $26.0 2.4% -0.15% 38M

|

Health Technology

| -36.8% | O: -0.05% H: 0.25% C: -0.52%
NVS | $94.36 1.93% 0.0% 2.3M

|

Health Technology

| 3.1% | O: -0.38% H: 1.25% C: 1.12%
GSK | News | $39.75 1.22% 0.0% 1.6M

|

Health Technology

| 13.01% | O: 0.26% H: 0.17% C: -0.09%
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| 124.38% | O: 0.36% H: 0.9% C: 0.55%
SNY | News | $46.32 2.05% 2.01% 3.3M

|

Health Technology

| -14.19% | O: 2.06% H: 0.0% C: 0.0%
report antibiotics global market

Innovent Announces Clinical Data of Multiple Trials Will be Presented at the AACR Annual Meeting 2023
Published: 2023-03-21 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

|

Health Technology

| -3.44% | O: 1.74% H: 0.0% C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| 125.05% | O: 0.24% H: 0.01% C: -0.99%
SNY | News | $46.32 2.05% 2.01% 3.3M

|

Health Technology

| -4.85% | O: 2.13% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M

|

Health Technology

| -28.83% | O: 0.13% H: 0.34% C: -1.12%
trials meeting

Chinook Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
Published: 2023-02-27 (Crawled : 01:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| 137.12% | O: -0.36% H: 0.0% C: -1.35%
EXEL | $22.51 0.09% 0.09% 2.3M

|

Health Technology

| 31.95% | O: -0.69% H: 1.67% C: -1.44%
KDNY | $40.39 0.22% -0.17% 0

|

Health Technology

| 87.25% | O: 1.76% H: 0.05% C: -0.59%
year therapeutics financial results

Innovent Announces First Participant Dosed in Phase 1 Clinical Study of IBI333 (VEGF-A/VEGF-C Bispecific Fusion Protein) in Patients with Neovascular Age-related Macular Degeneration
Published: 2023-02-28 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

|

Health Technology

| 137.12% | O: -0.36% H: 0.0% C: -1.35%
SNY | News | $46.32 2.05% 2.01% 3.3M

|

Health Technology

| -5.13% | O: -1.4% H: 0.0% C: 0.0%
ibi333 macular study phase 1

← Previous
1
2
3
4
5
6
Next →

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M

|

EGOX | $0.0515 43.06% 30.1% 330M

|

OLB 4 | $0.33 -14.95% 25.53% 840K

|

Technology Services

NVFY | $2.77 31.28% 23.83% 33M

|

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M

|

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M

|

Distribution Services

INSG | $3.03 25.21% 20.13% 330K

|

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K

|

WLGS | $0.59 18.0% 17.9% 2.3M

|

ASNS | $0.828 21.75% 17.86% 18K

|

Your saved searches

Save your searches and get alerts when important news are released.